Bill would limit gifts, allow sampling
Bill would limit gifts,allow sampling
Representative Pete Stark (D-CA) has introduced the "Save Money for Prescription Drug Research Act of 2000," a bill that would deny tax deductions for certain gifts provided to physicians by drug manufacturers. If passed, the bill would not apply to samples.
Stark accused the pharmaceutical industry of spending twice as much money on marketing and administration as it does on research and development and called gifts to doctors "bribes." "Rather than spending pharmaceutical dollars on these very questionable gifts, the industry should devote the billions of dollars on life-saving drugs," Stark said in an introductory speech.
The bill would apply to all gifts "provided directly or indirectly to or for the benefit of a physician, including gifts of meals, sponsored teachings, symposia and travel."
"The need for this bill is clear," Stark said. "Denying the pharmaceutical industry the ability to deduct expenditures for gifts (other than product samples) to physicians is a critical step in providing Americans with access to more life-saving drugs. This will discourage drug company gifts that have been shown to sway physician prescribing behavior and free up more pharmaceutical revenue for R&D. By redirecting drug company promotional expenditures to their R&D budgets, the American public would reap the benefit of increased medical breakthroughs." PR
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.